CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)

This study defines CRC2631/iSTORM as a tumor-selective microbial immunotherapy that exploits surface-exposed, mannose-rich N-glycans to colonize PDAC, delivers CMTM6 silencing, and restores CD8 + T-cell activation and tumor control in models resistant to PD-1 blockade immunotherapy. These findings provide a mechanistic blueprint for glycan-guided, CMTM6-targeted bacterial "living drugs," support rational combination strategies for deepening therapeutic effect, and establish a lyophilized, biocontained platform that could be developed into scalable microbial immunotherapies for PDAC and other immunologically cold solid tumors.

However, the interaction between CMTM6 and FAS is absent in human cells due to the difference in three amino acids at the boundary of the FAS extracellular and transmembrane domains. Altogether, our findings urge caution when translating promising data regarding the targeting of CMTM6 from mouse cancer models to potential human therapies.

Functionally, TSPAN4 knockdown in melanoma cells led to more efficient immune checkpoint blockade through PD-1 on T cells. This study identifies TSPAN4 as a negative regulator of PD-L1 at the cell surface of melanoma cells suggesting that targeting TSPAN4 may offer a new therapeutic strategy to enhance immune checkpoint blockade in melanoma and other cancers.

Our findings establish the tumor-intrinsic MAVS/CMTM6/CCL3 axis as a previously unrecognized critical regulator of senescence-driven antitumor immunity in renal carcinoma. Therapeutic targeting of this axis presents a promising strategy to curtail tumor progression and potentiate immunotherapy.

This functional interplay was corroborated in vivo, as WWP2 depletion enhanced tumor cell senescence and suppressed tumor growth, an effect that was partially rescued by concurrent CMTM6 knockdown. Taken together, our findings establish the WWP2-CMTM6-p21 axis as a pivotal regulatory mechanism of cellular senescence in HCC and shed new light on senescence-related therapeutic strategies for HCC.

RAI14, a skeleton protein, facilitated the macropinocytosis of MHC II molecules and tumor-associated antigen, thus activating Th1 cells in HCC. In conclusion, our study revealed how RNASEH2C mediated RAI14's lysosomal degradation, offering potential targets and strategies for HCC immunotherapy.

This work highlights the importance of targeting PD-L1 recycling and intrinsic signaling, specifically in myeloid cells, to boost antitumor responses. Our studies suggest that H1A can provide a solution to the lack of responses seen with current therapeutics, while also revealing previously unknown intrinsic functions of PD-L1 in myeloid cells.

This study identifies CMTM6 as a critical regulator of the immunosuppressive phenotype of microglia/macrophages in GBM. Targeting CMTM6 in microglia/macrophages may represent a novel strategy to reprogram the tumor immune microenvironment and improve the efficacy of immunotherapy in GBM.

[This retracts the article DOI: 10.3389/fmolb.2024.1452740.].

[This retracts the article DOI: 10.3389/fmolb.2022.983410.].

Furthermore, combination therapy with anti-PD-L1 and tandutinib significantly improved survival, suppressed leukemia cell expansion, and augmented the anti-leukemia T cell response in mice bearing FLT3-ITD+ leukemia...Furthermore, CMTM6 upregulation and protein interaction with FLT3 was validated in primary leukemia cells from two independent cohorts of patients with FLT3-ITD+ AML. Collectively, these findings uncover FLT3-mediated stabilization of CMTM6 in AML cells, which results in enhanced PD-L1 cell surface expression and leukemia immune escape.

According to the "Timeline visualization of references," classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.